Navigation Links
Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development
Date:6/17/2009

Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis

SEATTLE, June 17 /PRNewswire/ -- A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced today at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to fight tuberculosis (TB).

The two organizations will share their expertise and resources in the development of TMC207, which could become the first TB drug with a new mechanism of action in 40 years. The interim data from an ongoing Phase II study of TMC207 were recently published in the New England Journal of Medicine. In the placebo-controlled study of 47 patients with multidrug-resistant TB (MDR-TB), it was found that 48 percent of patients receiving TMC207 in combination with standard treatment converted to negative sputum culture after eight weeks compared with 9 percent of those who received placebo and standard treatment.

The collaboration will maximize the expertise and resources from both the public and private sectors with the intent to improve the treatment of one of the world's oldest and most deadly diseases. Increased efforts and resources to develop new and improved TB drugs are sorely needed. Among infectious diseases, tuberculosis is the second most common cause of adult deaths worldwide. The World Health Organization (WHO) estimates approximately one-third of the world's population is infected with Mycobacterium tuberculosis (M.tb), the bacillus that causes TB, and the disease is responsible for nearly 5,000 deaths per day, worldwide. MDR-TB, which is characterized by resistance to at least two of the most powerful medicines in today's standard, four-drug regimen for drug-susce
'/>"/>

SOURCE Tibotec Inc.; TB Alliance
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Unique role for blood formation gene identified
2. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
3. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
4. Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors
5. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
6. Graduates of Unique New Labor/Management Healthcare Workforce Training Program Honored Today in Oakland
7. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
8. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
9. The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa
10. Franco e Rizzi Offers Low-Cost Weight Loss Surgery (WLS) With Unique Price Guarantee
11. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced that they will welcome four new members to their ...
(Date:7/1/2015)... ORANGE, Calif. (PRWEB) , ... July 01, 2015 ... ... advanced orthodontic technology and services, today announced that its fifth annual Smile for ... has raised $80,000 for the non-profit organization. In addition to supporting S4L in ...
(Date:7/1/2015)... Japan (PRWEB) , ... July 01, 2015 , ... ... 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. ... Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May 2014. ...
(Date:7/1/2015)... ... ... The Collaborative for Children and Families (CCF) announced that it received a ... to improve quality of care and save costs for the child welfare sector by ... in New York’s Medicaid system. Experts agree that children need thorough solutions to live ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... after markets close at 2:00 p.m. PT (5:00 p.m. ET) ... MASI ), the inventor of Pulse CO-Oximetry and Measure-Through Motion ... quarter and fiscal year 2008 financial results for the period ... March 3, 2009.A conference call to review the results will ...
... Its Roster, Fielding Five Teams to Spread Personal Messages ... 1 and Type 2 DiabetesBRIDGEWATER, N.J., Feb. 5 ... glargine [rDNA origin] injection) and rapid-acting insulin Apidra(R) (insulin ... sponsors of Team Type 1, a team of amateur ...
... Feb. 5 Palomar Medical Technologies, Inc. (Nasdaq: ... light-based systems for cosmetic treatments, today announced financial results ... 2008. Revenues for the quarter ended December 31, ... product revenues, $2.2 million were royalty revenues, $0.5 million ...
... TORONTO, Feb. 5 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ... TTHI ) today announced the completion of patient ... gastrin analogue, TT-223, in patients with type 2 ... dose-ranging study to evaluate the safety, tolerability and ...
... Health Records (EHRs) have been promoted by industry and ... controlling costs. However, actual adoption of EHRs has ... to implementation costs, security, privacy, and systems integration. ... adoption barriers pale in comparison to basic usability and ...
... and identity theft response leader Kroll Fraud Solutions will host webinars ... a team of Kroll data security experts. , ... ... theft response leader Kroll Fraud Solutions will host a ...
Cached Medicine News:Health News:Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009 2Health News:Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009 3Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 2Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 3Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 4Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 5Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 6Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 3Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 4Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 5Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 6Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 8Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 9Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 10Health News:Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients 2Health News:How to Select an Electronic Health Record System That Healthcare Professionals Can Use 2Health News:Kroll Fraud Solutions To Host Free Webinar Series on Preparing for and Responding to a Healthcare Data Breach 2
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  AVACEN, Inc. ... a second AVACEN patent covering the medical technology platform supporting ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... The apparatus and methods patent no. 9,066,781 - Methods And ... devices manufactured by AVACEN and specific methods of use, referred ...
(Date:7/1/2015)... Fla. , July 1, 2015 Rock ... development company focused on chronic inflammatory disease and neurologic ... of principle study with anatabine citrate, the Company,s lead ... oral dose of anatabine citrate can significantly inhibit the ... subjects. The Company is developing this compound in a ...
(Date:7/1/2015)... , July 1, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... Bob Radie , president and chief executive officer, ... summer. He will provide an update on Egalet,s ... tromethamine) Nasal Spray, approved product OXAYDO ™ ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3
... -Study Results Show Cethromycin Not Associated with QT Prolongation- ... -Favorable Cardiac Safety Profile Strengthens NDA-, CHICAGO, ... ADLS ), today announced positive results from Trial,CL07-001, a ... cethromycin. This study was conducted to evaluate the cardiac,safety ...
... landscape of scientific,publications strategy, planning and delivery is ... global publications groups are fully,located in the marketing ... groups to increase clinical presentation, according to a ... a benchmarking study that included such influential companies ...
Cached Medicine Technology:Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 2Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 3Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 4Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 5Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 6Industry Executives Finding Value in Shift of Scientific Publications 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: